Alpha Tau Medical (DRTS) Income from Continuing Operations (2021 - 2026)
Alpha Tau Medical's (DRTS) quarterly Income from Continuing Operations came in at 22950000.0 in Q1 2026, up 170.22% year-on-year from 8493000.0 in Q1 2025, and up 88.02% quarter-over-quarter from 12206000.0 in Q4 2025.
Alpha Tau Medical (DRTS) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Alpha Tau Medical has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 22950000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 22950000.0, up 170.22% year-over-year; the trailing twelve-month figure through Mar 2026 was 56842000.0 (up 76.24% YoY), and the FY2025 annual result was 42385000.0, up 33.55% from the prior year.
- Income from Continuing Operations came in at 22950000.0 for Q1 2026 at Alpha Tau Medical, up from 12206000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 25740000.0 in Q1 2022 to a low of 1987000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 8145000.0 (2023), against an average of 9407058.82.
- Across the five-year window, Income from Continuing Operations sank 71.42% in 2022 and jumped 334.88% in 2023, its largest moves.
- Alpha Tau Medical's Income from Continuing Operations stood at 3390000.0 in 2022, then jumped by 116.78% to 7349000.0 in 2023, then rose by 28.89% to 9472000.0 in 2024, then rose by 28.86% to 12206000.0 in 2025, then jumped by 88.02% to 22950000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 22950000.0 (Q1 2026), 12206000.0 (Q4 2025), and 11702000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Alpha Tau Medical | 2,384.20 | -76.42 Mn | - | 22.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.95 Mn |
| Dec 31, 2025 | 12.21 Mn |
| Sep 30, 2025 | 11.70 Mn |
| Jun 30, 2025 | 9.98 Mn |
| Mar 31, 2025 | 8.49 Mn |
| Dec 31, 2024 | 9.47 Mn |
| Sep 30, 2024 | 6.92 Mn |
| Jun 30, 2024 | 7.36 Mn |
| Mar 31, 2024 | 7.98 Mn |
| Dec 31, 2023 | 7.35 Mn |
| Sep 30, 2023 | 4.99 Mn |
| Jun 30, 2023 | 8.64 Mn |
| Mar 31, 2023 | 8.15 Mn |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 2.61 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | 25.74 Mn |
| Dec 31, 2021 | 3.81 Mn |
| Sep 30, 2021 | 4.81 Mn |
| Jun 30, 2021 | 6.95 Mn |